Pharming
Pharming

Pharming

Biotechnology
WebsiteInvestor RelationsSEC
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

$792.7M

Market Cap • 10/23/2026

1988

(38 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Netherlands

Netherlands

Country

Valuation

P/B

2,9

P/S

—

P/EBITDA

—

P/OCF

22,6

P/FCF

23,1

P/E

93,3

BVPS

3,8

EPS

0,1

Market Cap

Market Cap

792,7M

EV

747,7M

EV/Revenue

0

EV/EBITDA

-2,7

EV/EBIT

-2,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-3%

Total Yield

-3%

Payout

0%

Retained Earnings

-278,2M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

5,5%

Capex/OCF

1,9%

SBC/OCF

40,8%

% PPE

4,4%

% Goodwill

0%

ROE

3,6%

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

31%

CAGR Net Income 5Y

-23,1%

CAGR EPS 5Y

-23,2%

CAGR OCF 5Y

-10,6%

Leverage

N.D./EBITDA

0,2

Debt/Equity

0%

Current Ratio

3

Quick Ratio

2,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium